Pulling SEC filings + quote and writing the call…

4D Molecular Therapeutics, Inc.
Next earnings Aug 10, 2026 · consensus $-1.04 EPS, $3.79M rev
Last earnings -4.7% on 2026-05-07
Revenue grew 230194.6% YoY; but unprofitable (net margin -164.4%).
4D Molecular Therapeutics, Inc. shows $85.2M in FY2025 revenue (+230194.6% YoY), a -164.4% net margin, and -27.7% ROE.
Sources: SEC EDGAR (CIK 0001650648, latest 10-Q filed 2026-05-07) · EODHD · as of 6/25/2026, 9:51:34 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $18.0M | $3.13M | $20.7M | $37.0K | $85.2M |
| Gross profit | — | — | — | — | — |
| Operating income | -$71.3M | -$110M | -$113M | -$188M | -$160M |
| Net income | -$71.3M | -$107M | -$101M | -$161M | -$140M |
| Diluted EPS | -$2.57 | -$3.32 | -$2.58 | -$2.98 | -$2.42 |
| Net margin | -395.4% | -3435.4% | -486.6% | -434778.4% | -164.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1071 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Last 90 days: 0 open-market buys · 2 sales
| 2026-06-23 | Bizily Scott Chief Legal Officer | Exercise | 9.81K @ $4.14 | $40.6K |
| 2026-06-23 | Bizily Scott Chief Legal Officer | Sell | 9.81K @ $12.00 | $118K |
| 2026-06-22 | Kirn David See Remarks | Sell | 115K @ $10.47 | $1.20M |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.